Which has preferable earnings & valuation, BDSX or TALK?

Talkspace has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 2.58 -$35.26M -$4.06 N/A Talkspace $228.87M 3.81 $7.79M $0.01 521.00

Is BDSX or TALK more profitable?

Talkspace has a net margin of 0.49% compared to Biodesix's net margin of -33.26%. Talkspace's return on equity of 1.03% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -33.26% -2,101.40% -35.65% Talkspace 0.49% 1.03% 0.88%

Does the media favor BDSX or TALK?

In the previous week, Talkspace had 1 more articles in the media than Biodesix. MarketBeat recorded 5 mentions for Talkspace and 4 mentions for Biodesix. Talkspace's average media sentiment score of 1.50 beat Biodesix's score of 0.58 indicating that Talkspace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talkspace 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CSTL or BDSX?

In the previous week, Castle Biosciences had 16 more articles in the media than Biodesix. MarketBeat recorded 20 mentions for Castle Biosciences and 4 mentions for Biodesix. Biodesix's average media sentiment score of 0.58 beat Castle Biosciences' score of 0.46 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FLGT or BDSX more profitable?

Fulgent Genetics has a net margin of -26.05% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -4.93% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -26.05% -4.93% -4.50% Biodesix -33.26% -2,101.40% -35.65%

Does the media prefer FLGT or BDSX?

In the previous week, Fulgent Genetics had 7 more articles in the media than Biodesix. MarketBeat recorded 11 mentions for Fulgent Genetics and 4 mentions for Biodesix. Biodesix's average media sentiment score of 0.58 beat Fulgent Genetics' score of -0.25 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MCTA or BDSX?

Biodesix has a consensus target price of $28.33, suggesting a potential upside of 28.61%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Charming Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has stronger earnings & valuation, MCTA or BDSX?

Charming Medical has higher earnings, but lower revenue than Biodesix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Charming Medical N/A N/A N/A N/A N/A Biodesix $88.50M 2.58 -$35.26M -$4.06 N/A

Does the media refer more to BDSX or TOI?

In the previous week, Oncology Institute had 1 more articles in the media than Biodesix. MarketBeat recorded 5 mentions for Oncology Institute and 4 mentions for Biodesix. Oncology Institute's average media sentiment score of 0.94 beat Biodesix's score of 0.58 indicating that Oncology Institute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncology Institute 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biodesix (BDSX) Competitors

$22.03 +0.83 (+3.92%)

Closing price 04:00 PM Eastern

Extended Trading

$22.00 -0.04 (-0.16%)

As of 07:34 PM Eastern

Compare

BDSX vs. TALK, CSTL, FLGT, MCTA, and TOI

Should you buy Biodesix stock or one of its competitors? MarketBeat compares Biodesix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodesix include Talkspace (TALK), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Charming Medical (MCTA), and Oncology Institute (TOI).

How does Biodesix compare to Talkspace?

Biodesix (NASDAQ:BDSX) and Talkspace (NASDAQ:TALK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 57.4% of Talkspace shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 23.5% of Talkspace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biodesix has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Talkspace has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Biodesix currently has a consensus price target of $28.33, suggesting a potential upside of 28.61%. Talkspace has a consensus price target of $5.56, suggesting a potential upside of 6.77%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than Talkspace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Talkspace	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Talkspace had 1 more articles in the media than Biodesix. MarketBeat recorded 5 mentions for Talkspace and 4 mentions for Biodesix. Talkspace's average media sentiment score of 1.50 beat Biodesix's score of 0.58 indicating that Talkspace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talkspace	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Talkspace has a net margin of 0.49% compared to Biodesix's net margin of -33.26%. Talkspace's return on equity of 1.03% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Talkspace	0.49%	1.03%	0.88%

Talkspace has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	2.58	-$35.26M	-$4.06	N/A
Talkspace	$228.87M	3.81	$7.79M	$0.01	521.00

Summary

Talkspace beats Biodesix on 13 of the 17 factors compared between the two stocks.

How does Biodesix compare to Castle Biosciences?

Castle Biosciences (NASDAQ:CSTL) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Castle Biosciences has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

In the previous week, Castle Biosciences had 16 more articles in the media than Biodesix. MarketBeat recorded 20 mentions for Castle Biosciences and 4 mentions for Biodesix. Biodesix's average media sentiment score of 0.58 beat Castle Biosciences' score of 0.46 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Castle Biosciences currently has a consensus target price of $42.00, indicating a potential upside of 38.20%. Biodesix has a consensus target price of $28.33, indicating a potential upside of 28.61%. Given Castle Biosciences' higher probable upside, research analysts plainly believe Castle Biosciences is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Castle Biosciences has a net margin of -5.43% compared to Biodesix's net margin of -33.26%. Castle Biosciences' return on equity of -4.15% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-5.43%	-4.15%	-3.45%
Biodesix	-33.26%	-2,101.40%	-35.65%

Castle Biosciences has higher revenue and earnings than Biodesix. Castle Biosciences is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.68	-$24.16M	-$0.66	N/A
Biodesix	$88.50M	2.58	-$35.26M	-$4.06	N/A

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Castle Biosciences beats Biodesix on 12 of the 15 factors compared between the two stocks.

How does Biodesix compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Fulgent Genetics has a net margin of -26.05% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -4.93% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Biodesix	-33.26%	-2,101.40%	-35.65%

Biodesix has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.55	-$60.51M	-$2.82	N/A
Biodesix	$88.50M	2.58	-$35.26M	-$4.06	N/A

Fulgent Genetics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Fulgent Genetics presently has a consensus price target of $27.00, indicating a potential upside of 53.32%. Biodesix has a consensus price target of $28.33, indicating a potential upside of 28.61%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Fulgent Genetics had 7 more articles in the media than Biodesix. MarketBeat recorded 11 mentions for Fulgent Genetics and 4 mentions for Biodesix. Biodesix's average media sentiment score of 0.58 beat Fulgent Genetics' score of -0.25 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fulgent Genetics beats Biodesix on 10 of the 17 factors compared between the two stocks.

How does Biodesix compare to Charming Medical?

Charming Medical (NASDAQ:MCTA) and Biodesix (NASDAQ:BDSX) are related small-cap companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

21.0% of Biodesix shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Biodesix had 4 more articles in the media than Charming Medical. MarketBeat recorded 4 mentions for Biodesix and 0 mentions for Charming Medical. Biodesix's average media sentiment score of 0.58 beat Charming Medical's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Charming Medical	Neutral
Biodesix	Positive

Charming Medical has higher earnings, but lower revenue than Biodesix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charming Medical	N/A	N/A	N/A	N/A	N/A
Biodesix	$88.50M	2.58	-$35.26M	-$4.06	N/A

Biodesix has a consensus target price of $28.33, suggesting a potential upside of 28.61%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Charming Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Charming Medical has a net margin of 0.00% compared to Biodesix's net margin of -33.26%. Charming Medical's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charming Medical	N/A	N/A	N/A
Biodesix	-33.26%	-2,101.40%	-35.65%

Summary

Biodesix beats Charming Medical on 9 of the 12 factors compared between the two stocks.

How does Biodesix compare to Oncology Institute?

Biodesix (NASDAQ:BDSX) and Oncology Institute (NASDAQ:TOI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Oncology Institute had 1 more articles in the media than Biodesix. MarketBeat recorded 5 mentions for Oncology Institute and 4 mentions for Biodesix. Oncology Institute's average media sentiment score of 0.94 beat Biodesix's score of 0.58 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncology Institute	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biodesix has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	2.58	-$35.26M	-$4.06	N/A
Oncology Institute	$502.73M	1.01	-$60.61M	-$0.37	N/A

Oncology Institute has a net margin of -7.42% compared to Biodesix's net margin of -33.26%. Oncology Institute's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Oncology Institute	-7.42%	N/A	-24.68%

Biodesix has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 4.4% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Biodesix presently has a consensus price target of $28.33, suggesting a potential upside of 28.61%. Oncology Institute has a consensus price target of $8.50, suggesting a potential upside of 65.69%. Given Oncology Institute's higher possible upside, analysts plainly believe Oncology Institute is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Oncology Institute beats Biodesix on 10 of the 17 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDSX vs. The Competition

Export

Metric	Biodesix	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$219.54M	$9.93B	$6.86B	$12.43B
Dividend Yield	N/A	2.54%	2.60%	10.03%
P/E Ratio	-5.43	25.38	280.72	24.99
Price / Sales	2.58	4.92	588.49	90.52
Price / Cash	N/A	26.44	28.64	34.82
Price / Book	-71.06	5.22	11.02	6.21
Net Income	-$35.26M	$312.25M	$3.48B	$347.49M
7 Day Performance	-0.86%	-0.20%	0.57%	0.89%
1 Month Performance	0.18%	-0.89%	-4.14%	-3.60%
1 Year Performance	203.28%	27.08%	63.23%	20.46%

Biodesix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDSX Biodesix	3.3655 of 5 stars	$22.03 +3.9%	$28.33 +28.6%	+191.9%	$219.54M	$88.50M	N/A	220	Upcoming Earnings
TALK Talkspace	3.3941 of 5 stars	$5.23 +0.1%	$5.56 +6.5%	+126.0%	$875.26M	$238.37M	523.02	500	Positive News Upcoming Earnings
CSTL Castle Biosciences	3.8641 of 5 stars	$24.41 -0.1%	$42.43 +73.9%	+91.1%	$738.54M	$339.92M	N/A	540	Earnings Report Analyst Forecast
FLGT Fulgent Genetics	2.1587 of 5 stars	$19.53 -0.2%	$27.00 +38.2%	-10.7%	$554.11M	$322.67M	N/A	1,315	Earnings Report
MCTA Charming Medical	N/A	$29.36 flat	N/A	N/A	$497.22M	$5.42M	N/A	49	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodesix (BDSX) Competitors

BDSX vs. TALK, CSTL, FLGT, MCTA, and TOI

How does Biodesix compare to Talkspace?

Summary

How does Biodesix compare to Castle Biosciences?

Summary

How does Biodesix compare to Fulgent Genetics?

Summary

How does Biodesix compare to Charming Medical?

Summary

How does Biodesix compare to Oncology Institute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodesix (BDSX) Competitors

BDSX vs. TALK, CSTL, FLGT, MCTA, and TOI

How does Biodesix compare to Talkspace?

Do institutionals & insiders hold more shares of BDSX or TALK?

Which has more volatility & risk, BDSX or TALK?

Do analysts recommend BDSX or TALK?

Does the media favor BDSX or TALK?

Is BDSX or TALK more profitable?

Which has preferable earnings & valuation, BDSX or TALK?

Summary

How does Biodesix compare to Castle Biosciences?

Which has more risk and volatility, CSTL or BDSX?

Does the media prefer CSTL or BDSX?

Do analysts recommend CSTL or BDSX?

Is CSTL or BDSX more profitable?

Which has higher earnings and valuation, CSTL or BDSX?

Do insiders & institutionals believe in CSTL or BDSX?

Summary

How does Biodesix compare to Fulgent Genetics?

Is FLGT or BDSX more profitable?

Which has higher earnings & valuation, FLGT or BDSX?

Which has more risk & volatility, FLGT or BDSX?

Do analysts prefer FLGT or BDSX?

Do institutionals & insiders have more ownership in FLGT or BDSX?

Does the media prefer FLGT or BDSX?

Summary

How does Biodesix compare to Charming Medical?

Do institutionals and insiders have more ownership in MCTA or BDSX?

Does the media favor MCTA or BDSX?

Which has stronger earnings & valuation, MCTA or BDSX?

Do analysts rate MCTA or BDSX?

Is MCTA or BDSX more profitable?

Summary

How does Biodesix compare to Oncology Institute?

Does the media refer more to BDSX or TOI?

Which has higher earnings and valuation, BDSX or TOI?

Is BDSX or TOI more profitable?

Which has more volatility & risk, BDSX or TOI?

Do insiders and institutionals hold more shares of BDSX or TOI?

Do analysts rate BDSX or TOI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools